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Abstract
The December 2011 5
th International Workshop on HIV Persistence during Therapy addressed the issue of HIV
persistence among 210 scientists from 10 countries involved in the study of HIV reservoirs and the search of an HIV
cure. High quality abstracts were selected and discussed as oral or poster presentations. The aim of this review is
to distribute the scientific highlights of this workshop outside the group as analyzed and represented by experts in
retrovirology, immunology and clinical research.
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Introduction
The 5
th international workshop on HIV persistence dur-
ing therapy was held in St. Maarten from December 6-9
and featured presentations from 210 scientists repre-
senting approximately 10 countries. Since its inception,
the goal of the workshop has been to provide a forum
for research aimed at understanding the mechanism by
which HIV-1 persists in the face of antiretroviral therapy
(ART) and to develop strategies with which to curtail
viral persistence and accelerate the objective of viral era-
dication. While ART has fundamentally impacted the
health of individuals living with HIV infection and
effects durable suppression of plasma viral RNA to
undetectable levels, current treatment regimens are
unable to eradicate the virus [1]. In addition, pathogenic
manifestations of HIV-1 infection are manifest despite
potent viral suppression. Therefore, it is clear that we
have to look beyond long-term maintenance of HIV-1
infection and ultimately develop strategies for viral
eradication.
Virology of HIV persistence
Models of HIV latency
The development of strategies to eliminate HIV-1 reser-
voirs that persist in the face of ART will require a com-
plete understanding of the nature of viral persistence and
latency and how these processes are regulated. While
latency is considered the single biggest obstacle to viral
eradication, how latency is established and regulated is
still not well understood. Most of the studies conducted
to date on viral latency have focused on models that
employ established cell lines. They have demonstrated
various forms of latency regulation and the role of host
cell cycle, epigenetic effects and other host cell factors
that can regulate viral latency. However, it is unclear as
to the extent to which these cell line models of viral
latency reflect the true nature of latency as it exists in
memory CD4
+ T cells [2]. For this reason, several investi-
gators have attempted to develop primary cell models of
viral latency so as to gain greater physiologic insight into
viral persistence and latency and more importantly, how
latency can be interrupted. Planelles et al. [3] described a
system for the establishment of latency in in vitro differ-
entiated central memory cells. The system uses periph-
eral blood mononuclear cells from healthy human
donors. Following isolation of naïve CD4
+ cells by nega-
tive selection, cells are activated with CD3 and CD28
antibodies in medium containing TGF-beta, anti interleu-
kin (IL)-12 and anti IL4 antibodies followed by culture in
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cent state where the majority of infected cells are latent.
Planelles et al. have previously demonstrated that these
latently infected cells can be re-activated by incubation
with CD3/CD28 antibodies. The investigators went on to
use this system to screen for anti-latency agents. The
investigators demonstrated that incubation with IL-2 +
IL-7 can induce homeostatic proliferation and reactiva-
tion in about 10% of the latently infected cells. However,
full reactivation of all latently infected cells in the cul-
tures required antigenic stimulation. While this study
describes a system that can be very useful for the screen-
ing of anti-latency agents, it highlights the concern that
agents inducing homeostatic proliferation may have the
potential to expand integrated proviruses through gene
duplication at mitosis. Nonetheless, this won’t impact the
majority of latent genomes that fail to become reactivated
during homeostatic proliferation and therefore, not
achieve the goal of eradicating latent provirus. An impor-
tant point to consider is whether homeostatic prolifera-
tion favors the duplication of archival and defective
provirus rather than latent provirus. It is unclear whether
latent provirus duplication by mitosis during homeostatic
proliferation leads to expression of the provirus and sub-
sequent clearance by cytopathic effects or by immune
clearance. Defective provirus would be less likely to be
cleared by these mechanisms. Therefore it would be
important to determine to what extent homeostatic pro-
liferation allows duplication of latent provirus without
subsequent clearance.
Continuing on with the theme of primary models of
viral latency, Garcia et al. [4] described the generation of
HIV latency in BLT humanized mice. Infected BLT mice
were administered an anti-retroviral regime comprising
daily injections of FTC, tenofovir and raltegravir. Resting
cells obtained from BLT mice on this anti-retroviral
regime could be stimulated ex vivo to produce virus. The
frequency of latently infected, resting cells was deter-
mined to be in the reaching of 9.9 per million CD4
+
T cells, which is in the range observed for patients on
suppressive therapy. The availability of an in vivo model
of viral latency extends the tools available for the analysis
of anti-latency drugs.
Role of myeloid cells
While the majority of research has focused on the role of
lymphoid reservoirs in viral persistence and latency, sev-
eral presentations focused on the role of myeloid cells in
viral persistence. A large body of research has demon-
strated the important association of animal lentiviruses
with myeloid-lineage cells and, in particular, macro-
phages. However, very little attention has focused on the
role of myeloid-lineage cells in the biology of primate
lentiviruses. Early studies demonstrated infection of
macrophage in the tissues such as the lung and central
nervous system (CNS) but, beyond that, there is no clear
understanding of whether macrophage support viral per-
sistence in patients on antiretroviral therapy or whether
latency is also manifest in macrophage or other myeloid-
lineage cells. Arguably, the strongest piece of experimen-
tal evidence supporting an essential role for macrophage
in primate lentivirus biology is the demonstration that
myeloid-lineage cells harbor an antiviral restriction that
is not exhibited by T cells and further, that the virus has
evolved a strategy to circumvent this restriction.
Clements et al. [5] discussed the role of macrophage in
establishment of viral reservoirs in the brain and spleen
in SIV infected macaques on a 4-drug antiretroviral
regime that provides a model for the study of viral persis-
tence in the CNS. While ART was able to suppress viral
replication in the brain, viral DNA was found to persist.
It remains to be determined as to the extent of macro-
phage involvement in the persistence of viral DNA and
whether a resident population of microglial cells consti-
tutes a viral reservoir or whether perivascular macro-
phages, infected in the periphery, migrate to the CNS to
maintain the viral reservoir. This theme was continued
by Russell et al. [6] who examined involvement of splenic
macrophages as well changes in this population during
SIV infection following antiretroviral treatment. Maca-
ques on a 4-drug antiretroviral regime recreated the
dynamics of suppression of plasma viremia in patients on
ART and also recreated low-level residual viremia. The
data was consistent with the contribution of infected
macrophages to this residual viremia in animals under-
going antiretroviral suppression. This promises to be a
very important model for the study of viral persistence
during therapy since it allows access to tissue reservoirs
that are not accessible in patients and, in particular, will
allow an investigation of the role played by the CNS in
viral persistence.
Immunology of HIV persistence
Establishment of HIV reservoirs
In addition to the viral mechanisms of HIV-1 persistence,
it is well established that the immune system plays a criti-
cal role in the establishment and persistence of a viral
reservoir during therapy [7]. Interestingly, both the
innate and adaptive arms of the immune system may
contribute to HIV persistence during ART. As innate
immune mechanisms fail short in controlling HIV repli-
cation during acute infection, HIV disseminates and
infects antigen-specific T cells and macrophages in lym-
phoid organs where it establishes its reservoir and per-
sists for years. Understanding the shortcoming of the
innate immune response is therefore important to deline-
ate the cascade of events leading to HIV persistence.
Lewin et al. [8] presented insight into how chemokines
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1 latency. The investigators demonstrated that resting
CD4
+ T-cells incubated with CCL19 and CCL21 receptor
chemokines, CXCL 10 and CCR 6 rendered them per-
missive to HIV-1 infection and provirus establishment.
Incubation with CCL 19 prior to infection activated
RhoA signaling and alteration of the actin network that
was sufficient for establishment of the integrated pro-
virus. Furthermore, integration of HIV-1 in resting cells
was also dependent upon PI3K pathway activation and
inhibitors of the PI3K pathway did not affect nuclear
localization of viral cDNA but prevented cDNA integra-
tion. Lewin et al. went on further to describe how dendri-
t i cc e l l sm a yp l a yar o l ei nt h ei n f e c t i o no fr e s t i n g
memory CD4
+ cells. Monocyte-derived dendritic cells
(myeloid DCs) promoted latent infection of resting mem-
ory CD4
+ cells when in co-culture but less efficiently
when cells were incubated separately. This suggests the
presentence of soluble factors that may play a role in the
promotion of CD4 latency by myeloid DCs.
Innate immunity
Lieberman et al. [9] outlined that although HIV intro-
duces many foreign nucleic acids into the cytosol, HIV
infection of T cells and macrophages does not trigger an
interferon (IFN) response. She proposed to identify the
mechanisms by which HIV escapes detection in these cell
subsets. She identified Trex1 (Three Prime Repair Exo-
nuclease I) as a potent inhibitor of IFN induction during
HIV infection of T cells and macrophage. Trex-1 digests
viral reverse transcripts and in its absence, HIV DNA sti-
mulated Type I IFN production. By using CD4 aptamer-
siRNA chimeras that selectively knockdown gene expres-
sion in CD4
+ T cells, monocytes and macrophages, she
demonstrated that the knockdown of CCR5, HIV Vif and
gag or Trex1 inhibit HIV transmission in tissue explants
and humanized mice.
Laguette et al. [10] discussed how the anti-viral restric-
tion, recently identified as SAMHD1, influences the inter-
play between primate lentiviruses and myeloid cells. The
genomes of primate lentiviruses are distinguishable from
their animal retrovirus counterparts by the presence of
additional small open reading frames that encode acces-
sory proteins including Vif, Vpu, Nef and Vpr/Vpx. An
explosion of research in the past several years has revealed
that these accessory proteins form an antiviral defense
against cellular antiviral proteins commonly referred to
“antiviral restriction factors”. Vif antagonizes the antiviral
action of the Apobec3 cytidine deaminases, Vpu antago-
nizes the antiviral action of tetherin/BST 2 and, in viruses
lacking a Vpu gene (HIV-2 and most SIV variants)
tetherin is antagonize by Nef. For several years, it was
apparent that the Vpr/Vpx proteins of primate lentiviruses
specially enhance viral infection in myleoid-lineage cells
and studies focusing on the Vpx protein of HIV-2/SIV
demonstrated that myeloid-lineage cells including mono-
cytes, macrophage and dendritic cells harbor a restriction
that is counteracted by Vpx. In the past year, research
from 2 groups identified the restriction as a deoxynucleo-
side triphosphate triphosphohydreolase called SAMHD1
[11,12]. SAMHD1 exerts a very potent antiviral effect on
primate lentiviruses such that infection of myeloid-lineage
cells by SIV is absolutely dependent upon a functional
Vpx gene. Intriguingly, although HIV-1 is antagonized by
SAMHD1, the Vpr gene of HIV-1 does not appear to have
the capacity to neutralize this restriction. Nevertheless,
HIV-1 can establish myeloid cell infection in the face of
SAMHD1 restriction. Therefore, it remains to be deter-
mined whether HIV-1 possesses some degree of resistance
to SAMHD1 restriction and whether this property impacts
its ability to persist within myeloid cell reservoirs. At least,
in the case of HIV-2/SIV, establishment of a macrophage
reservoir is dependent upon neutralization of SAMHD1
by Vpx. Since primate lentiviruses have evolved a strategy
to circumvent SAMHD1, and since this restriction is not
exhibited by lymphoid cells, it argues that primate lenti-
viruses must occupy myeloid-lineage cells for some reason
and it is tempting to speculate that myeloid-lineage cells
contribute to the persistence nature of primate lentivirus
infection.
Manel et al. [13] gave further insights into the impor-
tant role of DCs during HIV infection. DCs posses the
machinery to sense HIV-1 but the restriction imposed by
SAMHD1 prevents optimal sensing. Thus, restoring
HIV-1 replication in DCs by using Vpx may trigger
innate sensing, thereby promoting HIV-specific immu-
nity and inhibiting the infection of T cells in trans
through the production of type I IFN.
O’Doherty et al. [14] quantified HIV molecular forms in
Elite Controllers (EC), a rare population of subjects who
naturally control HIV replication. EC displayed low levels
of integrated DNA and high levels of unintegrated DNA,
suggesting a possible defect in HIV integration as
recently reported [15,16]. She further investigated the
ability of CTLs from these subjects to control the size of
the HIV reservoir by using an in vitro assay. Her data
suggested that latently infected cells continuously express
low levels of viral proteins and constitute targets for
HIV-specific T cell responses. In an in vitro killing assay,
EC displayed more effective removal of latently infected
CD4
+ T cells than chronic progressors.
Lichterfeld et al. [17] also presented data pertaining to
the susceptibility of CD4
+ T cells from EC to HIV-specific
CD8
+ T cell mediated killing. In a cytotoxicity assay, CD4
+
T cells from EC showed an increased susceptibility to CD8
mediated killing. Interestingly, a reduced susceptibility of
naïve CD4
+ T cells to CD8
+ T cells mediated killing was
associated with a lower viral reservoir in EC.
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of immune activation in HIV persistence during ART
[19]. Inflammatory biomarkers (hsCRP, IL-6 and D-
Dimer) as well as activation markers on CD8 T cells
remained elevated during ART when compared to unin-
fected controls. While T cell activation levels and cell-
based measures of viral persistence (proviral DNA and
v i r a lR N A )w e r ew e a k l ya s s o c i a t e di nt h eb l o o d ,t h e
association between these factors was much stronger in
gut mucosa. Deeks et al. summarized the recent results
from two Raltegravir intensification trials indicating that
this intervention did not modify the levels of T cells
activation in blood and rectum but may reduce them in
the terminal ileum [20,21].
Chomont et al. [22] listed behavioral and clinical para-
meters associated with the HIV reservoir size (CD4 and
CD8 counts, age, route of transmission). In a multivariate
analysis, only CD4
+ T cell nadir significantly predicted
levels of HIV proviral DNA. The evolution in the TCR
repertoire of virally suppressed subjects was correlated
with the genetic evolution of the viral reservoir, support-
ing a model in which the dynamic of the memory CD4
+
T cell compartment drives the dynamic of the latent
reservoir. In the second part of his talk, Chomont pre-
sented a novel assay aimed at monitoring HIV persis-
tence during ART. The assay, which uses authentic CD4
+
T cells from virally suppressed subjects, could also be
used to identify novel compounds aimed at reactivating
HIV production in latently infected cells.
Vandergeeten et al. [23] outlined that IL-7 and IL-15
are involved in the maintenance of the pool of memory
CD4
+ T cells and hypothesized that they may also contri-
bute to the persistence of latently infected cells. Both
cytokines induced proliferation, activation and survival of
CD4
+ T cells in vitro. Similarly, both IL-7 and IL-15
enhanced viral production in productively infected CD4
+
T cells isolated from HIV infected subjects. Strikingly,
the two cytokines differed in their ability to induce HIV
production in latently infected cells, with IL-15 being
much more efficient than IL-7. These results suggested
that IL-15 should be considered as a possible candidate
to force viral expression of the latent reservoir to achieve
HIV eradication.
Chirullo et al. [24] started their presentation by sum-
marizing the main results of a recently published article
[25] showing that the gold-based drug auranofin can
reduce the size of the SIV reservoir by downregulating the
CD27 receptor. Auranofin induced both phenotype
changes and cell-death, which were more pronounced in
the memory compartment. The effects of auranofin were
enhanced by Buthionine Sulfoximine, a drug used in che-
motherapy that reduces the levels of glutathione. This
strategy could be used to decrease the lifespan of the
latently infected cells thus restricting the viral reservoir
size [26].
Innovative therapeutic strategies
Designing eradication trials
Kuritzkes et al. [27] mentioned that although a number
of promising approaches have led to testable hypotheses
for an HIV cure, for which small animal and primate
models may provide preliminary information, ultimately
proof of concept and validation studies in human sub-
jects will be required. This leads to determine the nature
of end-points to be included in eradication trials (quan-
titative measures of HIV reservoirs, in blood and tissues)
and the requirement for analytic treatment interruption.
This one is the most rigorous way to assess a functional
cure (no viremia rebound) but is not without risks.
Finally, it is also important to define in which kind of
patients these trials will first be proposed: patients on
suppressive ART (which line?), well preserved immune
functions (EC?) or advanced disease, patients with
malignancies? This may depend of the outcome and the
potential risks of the strategies. However, it is challen-
ging to define an acceptable level of risk in the context
of generally safe and effective life-long therapy. If a
functional cure could be achieved with a period of treat-
ment with some toxic drugs, how much toxicity would
be acceptable? This could go from a small fatal risk (as
to pancreatitis with ddI) to a modest risk (as for coron-
ary artery bypass grafting: 1-2%) or a significant risk
(like with bone marrow transplants: 10-20%).
It will undeniably be concerted decisions to make
between patients scientists, ethic committees and fund-
ing agencies.
ART at acute HIV infection
The immunological and virological benefits of ART
initiation during the early steps of HIV infection have
been reported for more than 10 years [28,29]. Starting
ART during the first weeks of infection is associated
with a reduced magnitude of the HIV reservoir after
prolonged treatment. Importantly, a recent study indi-
cates that early and prolonged ART can even lead to a
natural and prolonged control of the viremia after treat-
ment interruption [30]. Preliminary results from two
studies aimed at identifying precisely the benefits and
the mechanisms by which early treatment limits the
seeding of the reservoir were presented at this
workshop.
Markowitz et al. [31] presented the 96 weeks results of
their single-site study of 3- vs. 5-drug therapy in early/
acute HIV infection. They compared Tenofovir/Emtrici-
tabine plus Atazanavir/ritonavir or Darunavir/ritonavir
to the same agents plus Raltegravir and Maraviroc.
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drug arm, 23 patients remained on study; and from 14
patients randomized to the 3-drug arm, 11 patients
remained on study.
At 96 weeks, 18 patients remained on study in the
5-drug arm, and 10 patients in the 3-drug arm. As
expected the 5-drug regimen achieved < 50 copies/ml of
plasma viremia faster, but at week 48 there were 3 virolo-
gical failures in the 5 drug arm, and none in the 3-drug
arm. No differences were found in terms of proviral
DNA levels or infectious virus titers between the 2 arms.
Overall, these results are quite disappointing but concern
a population of patients treated after a mean duration of
symptoms of acute infection of about 50 days.
On the contrary, Ananworanich et al. [32] treated truly
cases of acute infection. Their protocol selection allowed
to diagnose 74 patients, and to include 62 of them within
a few days after infection. From the 35 patients who were
analyzed at the time of the presentation, 12 were treated
at Fiebig stage I (5 days after the eclipse phase), 3 at Fie-
big II (10 days) and 17 at Fiebig III (13 days). The ART
regimens were Tenofovir/Emtricitabine/Efavirenz in 13
patients and the same regimen + Raltegravir and Mara-
viroc for the first 24 weeks in 22 patients. This trial is
still enrolling.
Before ART initiation, total HIV DNA in PBMC was sig-
nificantly lower in Fiebig I versus Fiebig III patients (p =
0.007) and the loss of CD4
+CCR5
+ T cells in sigmoid colo-
nincreased from Fiebig I to III stages (p = 0.0014). After
treatment initiation, a rapid and equivalent plasma HIV
RNA decline was observed with both regimens.
The percentage of CD4
+CCR5
+ T cells in sigmoid
colon significantly increased after antiretroviral treatment
in Fiebig III and IV subjects.
Total and integrated HIV DNA in PBMCs declined
significantly after Mega-ART and ART. Total HIV DNA
by week 24 was undetectable in 40% of patients. Inte-
grated HIV DNA by week 24 was undetectable in 80%
of patients.
Total and integrated HIV DNA in sigmoid colon
declined significantly after Mega-ART. Total HIV DNA by
week 24 was undetectable in 35% of patients. Integrated
HIV DNA by week 24 was undetectable in 78% of patients.
The frequency of PBMCs harboring HIV DNA during
acute HIV predicted HIV reservoir size after 24 weeks
of treatment (p < 0.0001).
Consequently, these studies tend to show that a smal-
ler reservoir size is obtained when ART is initiated very
early at acute infection, but no clear benefit is found by
adding more than 3 drugs in the combination.
Purge of the HIV reservoirs
Zack et al. [33] proposed a new way to deliver anti-
latency agents, like bryostatin, to cells. Following their
previous success at incorporating this activator together
with Nelfinavir into nanoparticles [34], they proposed to
use vaults, which are cellular organelles, as transporters.
Consequently, they engineered vaults to include Bryosta-
tin and found a positive effect in vitro on reactivation of
latent HIV.
Margolis et al. [35] presented the first set of results of a
trial testing Vorinostat, an HDAC inhibitor. Four patients
are currently enrolled in this study which needed a long
process of several years for administrative approval. It
involves a single 400 mg dose of Vorinostat and looks at
HIV expression in resting cells. Initially, the 4 patients
were selected as their resting CD4
+ cells showed increased
viral RNA expression in vitro f o l l o w i n gt h ep r e s e n c eo f
Vorinostat. From oncologic studies, it is known that the
peak of Vorinostat in plasma occurs between 4 and 8
hours after a single administration. A mean increase in
vivo of 4.4 fold of resting CD4
+ T cell associated full-
length RNA was observed after the administration of 400
mg of Vorinostat and sampling patients at around 6 hours
post administration.
P r o v o c a t i v ed a t aw e r ep r e s e n t e db yHernandez et al.
[36] suggesting that, beyond its antiretroviral effect, Mara-
viroc could activate NF-kB in patients regardless of the
tropism of their infecting virus. The protocol “TRO-
PISMCV” (NCT01060618) included naïve HIV-infected
patients with CCR5-tropic and non-CCR5 tropic viruses,
who received a 10 day monotherapy period of Maraviroc.
Activity of NF-kB was detected in 4/6 patients with R5
tropic viruses and in 2/3 patients with D/M tropic viruses.
This effect may persist in resting cells after withdrawal of
t h ed r u gi ns o m ep a t i e n t s .
Chen et al. [37,38] showed that the daphnane diterpene
Gnidimacrin activated HIV-1 replication and killed persis-
tently-infected cells at picomolar concentrations in vitro in
ACH-1 and U1 cells. In these models, Gnidimacrin was at
least 2,000-fold more potent than Prostratin.
ART potency
Whether or not ongoing HIV replication or propagation
persists during effective ART is not a new topic, but it
has recently been fuelled by the in vitro demonstration
that ART is quite ineffective at preventing direct HIV
cell-to-cell transfer [39].
Bringing the problem at the clinical level, Schacker et al.
[40] analyzed 12 patients starting a combination with
Tenofovir/Emtricitabine and Efavirenz, Atazanavir/ritona-
vir or Darunavir/ritonavir. Virological and pharmacologi-
cal measurements were done in PBMCs, inguinal lymph
node cells, lymphoid cells from colon and terminal ileum,
taken at baseline, months 1, 3 and 6. Concentrations of
intracellular drug active forms were measured by UPLC/
MS/MS with a limit of detection of 2.5 fmol/10
6 cells.
Although plasma viremia became undetectable within
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HIV continued to infect new cells in lymphoid tissues and
that the drugs rarely reached effective concentrations in
these tissues [41].
It will therefore be important to develop new ways of
drug delivery in lymphoid tissues, in particular for stra-
tegies purging HIV reservoirs, in order to protect unin-
fected cells in every compartment.
Immune modulation
Deeks et al. [18] argued that the host response during HIV
infection is a barrier to a cure. Inflammation may drive
HIV persistence through several non-mutually exclusive
mechanisms including negative regulator pathways like
the inhibitory receptor programmed death 1 (PD-1). PD-1
plays an active and reversible role in T cell exhaustion and
memory CD4
+ cells expressing PD-1 contain more pro-
viral DNA than those who do not. Immune therapies
based on the blockade of PD-1 interaction with its ligands
are supposed to increase HIV production and enhance
anti-HIV specific immune responses. The first clinical trial
using anti PD-1 antibodies (ACTG 5301) is under
approval. It is a single-arm pilot study to evaluate the
safety, pharmacokinetic profile, and effects of a single dose
of anti-PD-1 antibody in 40 chronically HIV-infected
patients receiving effective ART for more than 36 months.
As mentioned previously, Vandergeeten et al. [23] pre-
sented the potential use of IL-15 to reactivate HIV pro-
duction from latently-infected cells. IL-15 is 4 fold more
potent than IL-7 in vitro for reactivating the reservoir
while inducing much less cell proliferation. Conse-
quently, IL-15 is a possible candidate to achieve HIV
eradication, although IL-7 increases the number of CD4
+ T cells harboring HIV integrated DNA.
Gene therapy
Trying to mimic the “Berlin patient”, June et al. [42]
updated their results with zing finger nuclease (ZFN) to
modify CCR5 expression. Six patients with CD4 > 400
cells/mm
3 and undetectable viremia received a single
infusion of 1 × 10
10 modified cells. Four weeks after the
infusion, a structured treatment interruption (STI) was
planned for a maximum of 12 weeks. Although plasma
viremia rebounded in all cases within 4 weeks following
the STI, it began to decrease in 5 cases before ART was
resumed. In particular, “patient 205” who was heterozy-
gote for the CCR5 delta 32 mutation before ZFN therapy,
reached undetectable viral load by day 112. Conse-
quently, ZFN modified cells distributed and trafficked
normally compared to endogenous CD4
+ cells and
showed antiviral activity during STI.
Elimination of CCR5 expression is not expected to
directly impact the size of the latent reservoir. If the sta-
bility of the latent reservoir is extended by reservoir
replenishment, limiting target cell availability would, in
turn, reduce potential sources of the virus that drives
the replenishment and, in this scenario, an accelerated
decay of the latent reservoir would be expected. How-
ever if the intrinsic stability of the latent reservoir is
indeed measured in decades and there is no replenish-
m e n t ,t h e ni n t r o d u c t i o no fC C R 5 - n e g a t i v ec e l l sw o u l d
not alter the decay of the latent reservoir. This should
still produce a functional cure since any virus released
from reactivated latent cells would be unable to establish
new infections. Either scenario would be a significant
step forward since patients transduced with CCR5-nega-
tive stem cell would be predicted to control the virus in
the absence of ART.
Jerome et al. [43] have been developing a strategy that
employs homing endonucleases with specificity towards
conserved HIV sequences. Homing endonucleases able
to target sequences within HIV-1 env, pol, tat and vif
have been developed. While the emergence of viral
mutants with altered cleavage sites are likely to rapidly
emerge, investigators are exploring the simultaneous use
of several homing endonucleases to avoid the generation
of recognition site mutants. These approaches are at a
very early stage and numerous obstacles stand in the
way of their clinical application. The endonucleases
must exhibit exquisite target-site specificity then there is
the issue of delivery. Presumably, latently infected cells
are only distinguishable from uninfected cells by the
presence of an integrated set of viral genes. In the
a b s e n c eo fa n yv i r a lg e n ee x p r e s s i o n ,i tw i l lb ed i f f i c u l t
to deliver endonucleases (or any interfering gene pro-
duct for that matter) specifically to infected cells. This
would necessitate transducing all permissive cell targets
in the host. Nevertheless, the existence of these major
obstacles should not stand in the way of exploring any
possible strategies with which to eliminate latent or
chronically infected cells. Several presentations focused
on molecular strategies to limit target cell availability.
Conclusion
As anticipated, the 5
th International Workshop on HIV
Persistence led to the presentation and discussion of
exciting new data from research groups working
towards an HIV cure. Over the years, the control of
HIV reservoirs is progressively moving from bench to
bedside. The next edition of the workshop will be held
in Miami, Fl, 3-6 December, 2013.
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